Apex Biotechnology Corp. (TPE:1733)
Taiwan · Delayed Price · Currency is TWD 28.95
-0.05 (-0.17%)
Aug 13, 2025, 1:30 PM CST
Apex Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 2,032 | 1,852 | 1,677 | 2,244 | 2,132 | 2,005 | Upgrade | |
Revenue Growth (YoY) | 18.75% | 10.48% | -25.29% | 5.28% | 6.30% | -8.80% | Upgrade |
Cost of Revenue | 1,438 | 1,331 | 1,145 | 1,667 | 1,560 | 1,553 | Upgrade |
Gross Profit | 594.5 | 521.34 | 531.12 | 576.84 | 571.51 | 452.22 | Upgrade |
Selling, General & Admin | 228.87 | 231.31 | 224.26 | 234.83 | 216.77 | 198.49 | Upgrade |
Research & Development | 162.61 | 161.52 | 163.33 | 165.45 | 153.29 | 150.77 | Upgrade |
Operating Expenses | 399.94 | 392.88 | 389.4 | 400.28 | 366.56 | 348.9 | Upgrade |
Operating Income | 194.55 | 128.46 | 141.72 | 176.56 | 204.95 | 103.33 | Upgrade |
Interest Expense | -3.57 | -3.64 | -4.39 | -5.4 | -12.53 | -10.28 | Upgrade |
Interest & Investment Income | 4.55 | 4.34 | 3.2 | 1.15 | 2.01 | 2.72 | Upgrade |
Currency Exchange Gain (Loss) | 17.6 | 17.6 | 18.97 | 54.71 | -58.6 | -3.56 | Upgrade |
Other Non Operating Income (Expenses) | -28.34 | 2.13 | 3.2 | 0.32 | 17.41 | 11.6 | Upgrade |
EBT Excluding Unusual Items | 184.79 | 148.9 | 162.7 | 227.35 | 153.23 | 103.82 | Upgrade |
Gain (Loss) on Sale of Investments | 4.23 | 4.23 | -3.96 | -2.89 | 31.7 | 6.8 | Upgrade |
Asset Writedown | - | - | -17.78 | -24.89 | - | - | Upgrade |
Pretax Income | 189.02 | 153.13 | 140.96 | 199.58 | 184.94 | 110.62 | Upgrade |
Income Tax Expense | 26.66 | 25.02 | 25.25 | 18.12 | -17.35 | 15.99 | Upgrade |
Earnings From Continuing Operations | 162.37 | 128.1 | 115.71 | 181.45 | 202.29 | 94.63 | Upgrade |
Minority Interest in Earnings | -0.12 | -0.11 | 0.07 | 0.33 | -0.07 | 0.17 | Upgrade |
Net Income | 162.25 | 128 | 115.78 | 181.79 | 202.22 | 94.8 | Upgrade |
Net Income to Common | 162.25 | 128 | 115.78 | 181.79 | 202.22 | 94.8 | Upgrade |
Net Income Growth | 48.22% | 10.55% | -36.31% | -10.11% | 113.33% | -16.74% | Upgrade |
Shares Outstanding (Basic) | 99 | 100 | 100 | 100 | 100 | 100 | Upgrade |
Shares Outstanding (Diluted) | 100 | 100 | 100 | 101 | 106 | 113 | Upgrade |
Shares Change (YoY) | -0.12% | 0.08% | -0.34% | -4.70% | -6.53% | 0.05% | Upgrade |
EPS (Basic) | 1.63 | 1.28 | 1.16 | 1.82 | 2.03 | 0.95 | Upgrade |
EPS (Diluted) | 1.61 | 1.27 | 1.15 | 1.81 | 1.93 | 0.87 | Upgrade |
EPS Growth | 49.18% | 10.44% | -36.46% | -6.16% | 120.97% | -16.21% | Upgrade |
Free Cash Flow | 243.12 | 300.43 | 208.48 | -9.97 | 153.28 | 235.35 | Upgrade |
Free Cash Flow Per Share | 2.42 | 2.99 | 2.08 | -0.10 | 1.45 | 2.08 | Upgrade |
Dividend Per Share | 1.200 | 1.200 | 1.100 | 1.400 | 1.300 | 1.100 | Upgrade |
Dividend Growth | 9.09% | 9.09% | -21.43% | 7.69% | 18.18% | - | Upgrade |
Gross Margin | 29.25% | 28.15% | 31.68% | 25.70% | 26.81% | 22.55% | Upgrade |
Operating Margin | 9.57% | 6.94% | 8.45% | 7.87% | 9.62% | 5.15% | Upgrade |
Profit Margin | 7.98% | 6.91% | 6.91% | 8.10% | 9.49% | 4.73% | Upgrade |
Free Cash Flow Margin | 11.96% | 16.22% | 12.44% | -0.44% | 7.19% | 11.74% | Upgrade |
EBITDA | 246.47 | 182.03 | 206.52 | 260.08 | 291.6 | 199.83 | Upgrade |
EBITDA Margin | 12.13% | 9.83% | 12.32% | 11.59% | 13.68% | 9.96% | Upgrade |
D&A For EBITDA | 51.91 | 53.56 | 64.8 | 83.52 | 86.65 | 96.51 | Upgrade |
EBIT | 194.55 | 128.46 | 141.72 | 176.56 | 204.95 | 103.33 | Upgrade |
EBIT Margin | 9.57% | 6.94% | 8.45% | 7.87% | 9.62% | 5.15% | Upgrade |
Effective Tax Rate | 14.10% | 16.34% | 17.91% | 9.08% | - | 14.45% | Upgrade |
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.